A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation
ConclusionsLusutrombopag 3 mg once daily for 7 days was effective without raising concerns about excessive increases in platelet count.Clinical trial registrationThe study is registered at JapicCTI-121944.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Gastroenterology | Japan Health | Liver | Liver Disease | Study | Thrombocytopenia | Thrombosis | Urology & Nephrology